Top of the morning to you. A sunny day is unfolding here on the Pharmalot corporate campus, where we are celebrating the end of another school year with a delicious cup of stimulation. For the next several weeks, we will no longer need to hustle about each morning and can, instead, focus on the tasks at hand. And so, time to get started. Here are some tidbits to get you going while we dive into our reading list. Hope your day goes well and let us know if you hear anything interesting...
Arkansas Judge Denies J&J Request For New Risperdal Trial (Associated Press)
Patients Drive Direction Of New Drug Research (Boston Globe)
Carl Icahn Names Four Nominees To Forest Board (Associated Press)
Protesters At BIO Push FDA Over Breast Cancer Drug (Boston Business Journal)
Alexion Wins State Aid For 300 Jobs In Connecticut (CBS News)
AstraZeneca And Palatin End Obesity Drug Trial (Pharma Times)
CSL Confirms Fluvax Manufacturing Linked To Convulsions (Bloomberg News)
Drugmakers And Massachusetts Form Neuroscience Consortium (Boston Globe)
Spanish Drugmakers Sound Alarm On Regional Debt (Reuters)
Pfizer Says Xalkori Lung Cancer Drug Met Study Goal (Associated Press)
FDA Wants To Continue Pilot Supply Chain Program (Regulatory Focus)
Alnylam Gets Orphan Status For Neurodegenerative Disease Drug (Associated Press)
AMRI Expects Another Round Of Cost-Cutting (Outsourcing Pharma)
AstraZeneca And Rigel Strike Asthma Drug Deal (San Francisco Business Times)
EDITOR'S NOTE: Please check this post for updates during the day
4 Comments
Let's hope you never develop a resistance to coffee. And that you "savor the morning stillness" - if only for those few blessed weeks!
Blood was shed in those days in pursuit of a cause, but something tells me the pink ribbon crowd these days is only willing to go so far.
Read and learn.
http://www.actupny.org/documents/FDAhandbook1.html